...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith trial partners

"However, the first home run for ZEN-3694 in collaboration with a BP, management may decide to sell off the epigenetic drug. What they will do with the cash is another story."

 

yep, wouldn't surprise me if a portion of cash/maybe large flowed into rvx?- don't believe this would be very fair to those who just held zen & not so sure how folks who held both would feel either? If a person just held rvx , prob good?

not sure how or IF any of the above could or will happen?

Share
New Message
Please login to post a reply